Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

被引：0
作者：
Toshihiko Doi
Kenji Tamura
Yuko Tanabe
Kan Yonemori
Takayuki Yoshino
Nozomu Fuse
Makoto Kodaira
Hideaki Bando
Kazuo Noguchi
Takashi Shimamoto
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Exploratory Oncology Research & Clinical Trial Center
[2] National Cancer Center Hospital,undefined
[3] National Cancer Center,undefined
[4] MSD K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
MK-2206; pan-AKT inhibitor; Pharmacokinetics; Phase I study; Skin toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 416
页数：7
相关论文
共 50 条
  • [21] A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
    Okamoto, Wataru
    Yoshino, Takayuki
    Takahashi, Toshiaki
    Okamoto, Isamu
    Ueda, Shinya
    Tsuya, Asuka
    Boku, Narikazu
    Nishio, Kazuto
    Fukuoka, Masahiro
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1063 - 1071
  • [22] A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Honda, Kazunori
    Asahina, Hajime
    Tamura, Yosuke
    Hozak, Rebecca R.
    Gao, Ling
    Suzukawa, Kazumi
    Enatsu, Sotaro
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (04) : 298 - 305
  • [23] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
  • [24] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [25] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    Papadopoulos, K. P.
    El-Rayes, B. F.
    Tolcher, A. W.
    Patnaik, A.
    Rasco, D. W.
    Harvey, R. D.
    LoRusso, P. M.
    Sachdev, J. C.
    Abbadessa, G.
    Savage, R. E.
    Hall, T.
    Schwartz, B.
    Wang, Y.
    Kazakin, J.
    Shaib, W. L.
    BRITISH JOURNAL OF CANCER, 2017, 117 (11) : 1592 - 1599
  • [26] Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
    Shimizu, Toshio
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Kawakami, Hisato
    Watanabe, Satomi
    Yamamoto, Noboru
    Yonemori, Kan
    Koyama, Takafumi
    Sato, Jun
    Tamura, Kenji
    Kikuchi, Keiichi
    Akaike, Kenichiro
    Takeda, Shiho
    Takeda, Masayuki
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 1 - 12
  • [27] Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
    Toshio Shimizu
    Kazuhiko Nakagawa
    Hidetoshi Hayashi
    Tsutomu Iwasa
    Hisato Kawakami
    Satomi Watanabe
    Noboru Yamamoto
    Kan Yonemori
    Takafumi Koyama
    Jun Sato
    Kenji Tamura
    Keiichi Kikuchi
    Kenichiro Akaike
    Shiho Takeda
    Masayuki Takeda
    Investigational New Drugs, 2023, 41 : 1 - 12
  • [28] A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104)
    Ho, Alan L.
    Foster, Nathan R.
    Vasudeva, Shyamprasad Deraje
    Katabi, Nora
    Antonescu, Cristina R.
    Frenette, Gary P.
    Pfister, David G.
    Erlichman, Charles
    Schwartz, Gary K.
    CANCER, 2024, 130 (05) : 702 - 712
  • [29] Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Uenaka, Kazunori
    Sekiguchi, Risa
    Makiuchi, Takeshi
    Slapak, Christopher A.
    Benhadji, Karim A.
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1645 - 1655
  • [30] Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Kazunori Uenaka
    Risa Sekiguchi
    Takeshi Makiuchi
    Christopher A. Slapak
    Karim A. Benhadji
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1645 - 1655
12345